Tagged with BI

Denmark Kasper Møller, Chief Technical Officer and General Manager of AGC Biologics Denmark, shares insights into the company’s strategic priorities and the role of its Copenhagen facility in AGC Biologics’ global network. Møller discusses the ongoing expansion of the site, the growing complexity of biologics manufacturing, and the evolving demands of…

Switzerland Riad Sherif, CEO of Oculis, leads strategic innovation in ophthalmology and neuro-ophthalmology. With over 25 years of global experience, he has built a highly differentiated late-stage pipeline focused on addressing unmet medical needs through visionary innovations. Under his leadership, Oculis has grown from a hospital project with a single asset…

Belgium The latest stories from healthcare and the life sciences in Belgium, the Netherlands and Luxembourg (BeNeLux). UCB is considering a USD five billion investment in the US to avoid President Trump’s tariffs on the EU; Belgium’s competition authority fines three consumer healthcare companies; and the launch of a EUR 200…

Denmark Christian Houborg, General Manager and Senior Vice President of FUJIFILM Biotechnologies Denmark, shares how the Hillerød site has evolved from a legacy facility into a cornerstone of the company’s global CDMO network. From expanding capacity to embracing cutting-edge technologies like AI and digitalisation, FUJIFILM Biotechnologies is setting new standards for…

Denmark Hans Schambye brings decades of experience across academia, biotech start-ups, and industry leadership. Now CEO of Galecto – which develops small molecules for the treatment of cancer and severe liver disease – and chairman of DANISH BIO, he has led clinical development, financing, and partnerships in both Europe and the…

Hong Kong At first glance, tiny and crowded Hong Kong may not look like an obvious destination for developing next-generation gene therapies, for all its financial firepower and international complexion. Delve deeper, however, and its distinctive and differentiated offering becomes ever more apparent.    “While Hong Kong’s biomedical ecosystem certainly still lags…

Denmark Ian Laquian’s journey from Big Pharma strategy leadership to entrepreneurial venture creation exemplifies the innovative thinking required to address intractable neurological challenges. Having spearheaded CNS therapeutic area strategy at Takeda Pharmaceuticals, Laquian has pioneered a ground-breaking approach that leverages metabolic pathways to treat neurodegenerative diseases. Through the establishment of Kariya…

MEA A selection of top stories coming out of the Middle East and Africa’s pharma sector: Egypt’s Gypto Pharma partners with US drugmaker Dawa to expand the local production of medicines; Jordan’s Hikma makes a USD 1 billion investment pledge for US manufacturing and R&D, and Riyadh-headquartered private equity firm Jadwa…

Denmark As Denmark positions itself as a rising force in global life sciences, the BioInnovation Institute (BII) stands at the centre of this momentum, bridging world-class academic research with entrepreneurial ambition. In this conversation, CEO Jens Nielsen shares how BII is scaling its proven model, shaping Denmark’s innovation environment, and drawing…

Switzerland Alexander Salzmann with nearly a decade at Sandoz, reflects on the company’s transition from a Novartis division to an independent, Swiss-listed entity. In this interview, Salzmann discusses the challenges and opportunities of operating a business in the company’s home market Switzerland, and the Sandoz ambition to lead the generics and…

Denmark Christof Bischoff, Country Director of AstraZeneca Denmark, draws on over two decades of international and national experience to navigate one of Europe’s most advanced yet complex healthcare environments. In this interview, he reflects on the affiliate’s evolution from a traditional commercial operation to a system-oriented partner driving innovation across clinical…

Switzerland From regenerating damaged muscles to rewriting the cell manufacturing playbook, Switzerland’s next wave of biotech innovators is turning regenerative medicine into a precision science. Once considered futuristic, technologies like autologous tissue grafts, gene-edited therapies, and cell-state reprogramming are now gaining real-world traction with Swiss startups at the forefront. These five…